SNWVHIGH SIGNALRISK10-K

SNWV disclosed material accounting errors requiring restatement of previously issued financial statements, while shares outstanding increased and prior FDA-related risk language was removed.

The company acknowledged material misstatements in sales tax accounting that affect multiple prior periods, requiring investors to disregard previously published financial information. This represents a significant internal controls failure and raises questions about the reliability of financial reporting processes. The removal of FDA approval risk language alongside the accounting restatement creates additional uncertainty about disclosure completeness.

Comparing 2026-03-26 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

The company showed solid growth with revenue expanding 35% and gross profit increasing 38.4%, while accounts receivable grew substantially reflecting the higher sales volume. The balance sheet strengthened notably with current liabilities declining 25.6% and interest expense dropping significantly from $4.5M to $1.8M, suggesting improved debt management. However, these positive financial trends must be viewed cautiously given the disclosed accounting errors and required restatements of prior period results.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+62.9%
$3.3M→$5.4M

Receivables surged 62.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Interest Expense
P&L
-59.2%
$4.5M→$1.8M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
+57.9%
$2.5M→$3.9M

Operating cash flow surged 57.9% — exceptional cash generation, highest quality earnings signal.

Inventory
Balance Sheet
+43%
$4.1M→$5.9M

Inventory surged 43% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Gross Profit
P&L
+38.4%
$24.6M→$34.0M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+35%
$32.6M→$44.1M

Strong top-line growth of 35% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+33.9%
$18.4M→$24.6M

Current assets grew 33.9% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
-25.6%
$24.0M→$17.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
+24%
$30.1M→$37.3M

Asset base grew 24% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
-17.3%
$43.2M→$35.7M

Liabilities reduced 17.3% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-20
ADDED
As of March 24, 2026 , there were issued and outstanding 8,594,209 shares of the registrant s common stock.
Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
During the preparation of this Annual Report on Form 10-K, the Company determined that it had not appropriately accounted for certain transactions under US GAAP.
For the years ended December 31, 2024 and 2025, presented, the transactions related to sales tax, which led to an understatement of accrued expenses and a corresponding, non-recurring increase in expense due to the recognition of previously unrecorded taxes, associated interest, and penalties.
In accordance with Staff Accounting Bulletin ( SAB ) 99, Materiality , and SAB 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements , the Company evaluated the materiality of the errors from qualitative and quantitative perspectives, individually and in the aggregate, and concluded that the errors in aggregate were material to the consolidated financial statements for the affected periods.
Accordingly, previously issued financial information for the periods indicated above, as included in the Company s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, earnings releases, and similar communications, should no longer be relied upon and is superseded by the information contained in this Annual Report.
The Company s patented and FDA cleared product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds.
The Company is backed by an intellectual property ( IP ) portfolio of over 60 patents.
In the year ended December 31, 2025 , we had total revenues of $44.1 million , a 35% increase from revenues of $32.6 million in the year ended December 31, 2024 .
UltraMIST systems and consumables represented approximately 99% of 2025 revenues versus 98% of revenues in 2024.
REMOVED
As of March 18, 2025 , there were issued and outstanding 8,548,473 shares of the registrant s common stock.
Food and Drug Administration ("FDA") approval of new products and new uses of our current products; financial markets; the competitive environment; supplier and customer disputes; and our plans to remediate our material weaknesses in our disclosure controls and procedures and our internal control over financial reporting.
The Company s patented and FDA cleared products include the UltraMIST system (UM) and the PACE family of products, both of which are used to treat a variety of acute and chronic wounds.
These products are backed by an intellectual property ( IP ) portfolio of over 165 patents.
In the year ended December 31, 2024 , we had total revenues of $32.6 million , a 60% increase from revenues of $20.4 million in the year ended December 31, 2023 .
UltraMIST systems and consumables represented approximately 98% of 2024 revenues versus 90% of revenues in 2023.
Our Products and Services: The Company currently markets directed energy products using both ultrasound and high energy acoustic shockwaves.
This proprietary technology has been shown to speed healing and reduce reported pain, and it has been cleared by the FDA for wound healing and debridement for a variety of acute and chronic wounds including: diabetic foot ulcers, venous leg ulcers, split thickness wounds/skin grafts, deep tissue pressure injuries, surgical wounds, and many more wound types.
by the FDA (K140782) and has CMS schedule one reimbursement under code 97610.
Sanuwave s Energy First protocol is at the forefront of improving the standard of care for advanced and chronic wounds.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →